UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The clinical pharmacokinetics of darifenacin

Clinical pharmacokinetics, 2006-01, Vol.45 (4), p.325-350

SKERJANEC, Andrej

2006

Volltextzugriff (PDF)

A large multi-center, randomized, double-blind, crossover study in healthy volunteers to compare pharmacokinetics and pharmacodynamics of a proposed biosimilar pegfilgrastim with EU and US reference pegfilgrastim: Methodological approach

Annals of oncology, 2018-10, Vol.29, p.viii637-viii637

2018

Volltextzugriff (PDF)

307 Population pharmacokinetic and pharmacodynamic modeling of bevacizumab and a proposed biosimilar (GP2019) in healthy male volunteers

European journal of cancer (1990), 2015-09, Vol.51, p.S56-S57

2015

Volltextzugriff (PDF)

Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys

mAbs, 2015-09, Vol.7 (5), p.829-837

2015

Volltextzugriff (PDF)

QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M 3 Selective Receptor Antagonist for the Treatment of Overactive Bladder

Journal of clinical pharmacology, 2005-09, Vol.45 (9), p.1038-1047

2005

Volltextzugriff (PDF)

Abstract P3-14-10: Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P3-P3-14-10

2018

Volltextzugriff (PDF)

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX

European heart journal, 2016-04, Vol.37 (14), p.1122-1130

2016

Volltextzugriff (PDF)

Biodistribution and plasma protein binding of zoledronic acid

Drug metabolism and disposition, 2008-10, Vol.36 (10), p.2043-2049

2008

Volltextzugriff (PDF)

1796PA large multi-center, randomized, double-blind, crossover study in healthy volunteers to compare pharmacokinetics and pharmacodynamics of a proposed biosimilar pegfilgrastim with EU and US reference pegfilgrastim: Methodological approach

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Randomized, double-blind, cross-over phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references

Annals of oncology, 2019-10, Vol.30, p.v738

2019

Volltextzugriff (PDF)

1815P - Randomized, double-blind, cross-over phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references

Annals of oncology, 2019-10, Vol.30, p.v738-v738

2019

Volltextzugriff (PDF)

1815PRandomized, double-blind, cross-over phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development

Arteriosclerosis, thrombosis, and vascular biology, 2010-12, Vol.30 (12), p.2372-2384

2010

Volltextzugriff (PDF)

A32 NEW ASTHMA THERAPIES: CLINICAL STUDIES: Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Qge031, A High Affinity Anti-Ige Antibody In Caucasian And Japanese Atopic Subjects

American journal of respiratory and critical care medicine, 2014-01, Vol.189, p.1

2014

Volltextzugriff (PDF)

Divergent effects of raloxifene HCl on the the pharmacokinetics and pharmacodynamics of warfarin

Pharmaceutical research, 2001-07, Vol.18 (7), p.1024-1028

2001

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics and safety of QGE 031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects

Clinical and experimental allergy, 2014-11, Vol.44 (11), p.1371-1385

2014

Volltextzugriff (PDF)

Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients

American journal of transplantation, 2003-07, Vol.3 (7), p.846-854

2003

Volltextzugriff (PDF)

B21 TRANSLATIONAL ASTHMA RESEARCH: A Predictive Model For Determining The Efficacy Of Multiple Doses Of Qge031 (ligelizumab) Versus Omalizumab And Placebo In Inhibiting The Allergen-Induced Early Asthmatic Response

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

Improving the quality of care for women with cardiovascular disease: report of a DCRI Think Tank, March 8 to 9, 2007

The American heart journal, 2008-11, Vol.156 (5), p.816-825

2008

Volltextzugriff (PDF)

Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs

The Journal of pharmacology and experimental therapeutics, 1996-08, Vol.278 (2), p.817

1996

Volltextzugriff (PDF)

Regular dosing of zoledronic acid maintains continuous suppression of osteolysis in patients with malignant bone disease

Bone (New York, N.Y.), 2008-03, Vol.42, p.S107-S108

2008

Volltextzugriff (PDF)

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized

Pediatric rheumatology online journal, 2013-11, Vol.11 (S1), p.A133-A133, Article A133

2013

Volltextzugriff (PDF)

Darifenacin, an M selective receptor antagonist (M SRA), does not prolong QT/QT

Clinical pharmacology and therapeutics, 2005-02, Vol.77 (2), p.P10-P10

2005

Volltextzugriff (PDF)

Darifenacin, an M3 selective receptor antagonist (M3 SRA), does not prolong QT/QTC

Clinical pharmacology and therapeutics, 2005-02, Vol.77 (2), p.P10-P10

2005

Volltextzugriff (PDF)

Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin

Pharmaceutical research, 2001-07, Vol.18 (7), p.1024

2001

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Aktive Filter

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(63)

Publikationsform

Sprache

Englisch
(75)
Slowenisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(34)
Humans
(21)
Biological And Medical Sciences
(14)
Female
(13)
Medical Sciences
(12)
Physical Sciences
(12)
Male
(11)
Pharmacology & Pharmacy
(11)
Aged
(10)
Middle Aged
(10)
Heart Attacks
(9)
Double-Blind Method
(8)
Environmental Sciences & Ecology
(8)
Animals
(7)
Cardiovascular System & Cardiology
(7)
Treatment Outcome
(7)
Adenosine Monophosphate - Analogs & Derivatives
(6)
Cardiac & Cardiovascular Systems
(6)
Drug Therapy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The clinical pharmacokinetics of darifenacin

A large multi-center, randomized, double-blind, crossover study in healthy volunteers to compare pharmacokinetics and pharmacodynamics of a proposed biosimilar pegfilgrastim with EU and US reference pegfilgrastim: Methodological approach

307 Population pharmacokinetic and pharmacodynamic modeling of bevacizumab and a proposed biosimilar (GP2019) in healthy male volunteers

Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys

QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M 3 Selective Receptor Antagonist for the Treatment of Overactive Bladder

Abstract P3-14-10: Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX

Biodistribution and plasma protein binding of zoledronic acid

1796PA large multi-center, randomized, double-blind, crossover study in healthy volunteers to compare pharmacokinetics and pharmacodynamics of a proposed biosimilar pegfilgrastim with EU and US reference pegfilgrastim: Methodological approach

Randomized, double-blind, cross-over phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references

1815P - Randomized, double-blind, cross-over phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references

1815PRandomized, double-blind, cross-over phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references

Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development

A32 NEW ASTHMA THERAPIES: CLINICAL STUDIES: Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Qge031, A High Affinity Anti-Ige Antibody In Caucasian And Japanese Atopic Subjects

Divergent effects of raloxifene HCl on the the pharmacokinetics and pharmacodynamics of warfarin

Pharmacokinetics, pharmacodynamics and safety of QGE 031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects

Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients

B21 TRANSLATIONAL ASTHMA RESEARCH: A Predictive Model For Determining The Efficacy Of Multiple Doses Of Qge031 (ligelizumab) Versus Omalizumab And Placebo In Inhibiting The Allergen-Induced Early Asthmatic Response

Improving the quality of care for women with cardiovascular disease: report of a DCRI Think Tank, March 8 to 9, 2007

Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs

Regular dosing of zoledronic acid maintains continuous suppression of osteolysis in patients with malignant bone disease

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized

Darifenacin, an M selective receptor antagonist (M SRA), does not prolong QT/QT

Darifenacin, an M3 selective receptor antagonist (M3 SRA), does not prolong QT/QTC

Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin

Aktive Filter

Suchergebnisse filtern